- Home
- HAFN vs IDYA Comparison
HAFN vs IDYA Comparison
Compare HAFN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- IDYA
- Stock Information
- Founded
- HAFN 2012
- IDYA 2015
- Country
- HAFN Bermuda
- IDYA United States
- Employees
- HAFN N/A
- IDYA N/A
- Industry
- HAFN
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- IDYA Health Care
- Exchange
- HAFN Nasdaq
- IDYA Nasdaq
- Market Cap
- HAFN 3.0B
- IDYA 2.6B
- IPO Year
- HAFN N/A
- IDYA 2019
- Fundamental
- Price
- HAFN $5.26
- IDYA $26.64
- Analyst Decision
- HAFN Strong Buy
- IDYA Strong Buy
- Analyst Count
- HAFN 1
- IDYA 12
- Target Price
- HAFN $10.00
- IDYA $53.08
- AVG Volume (30 Days)
- HAFN 2.1M
- IDYA 750.6K
- Earning Date
- HAFN 01-01-0001
- IDYA 11-04-2024
- Dividend Yield
- HAFN 30.73%
- IDYA N/A
- EPS Growth
- HAFN N/A
- IDYA N/A
- EPS
- HAFN 1.56
- IDYA N/A
- Revenue
- HAFN $2,970,261,000.00
- IDYA $3,922,000.00
- Revenue This Year
- HAFN N/A
- IDYA N/A
- Revenue Next Year
- HAFN N/A
- IDYA $158.10
- P/E Ratio
- HAFN $3.37
- IDYA N/A
- Revenue Growth
- HAFN 18.39
- IDYA N/A
- 52 Week Low
- HAFN $5.13
- IDYA $26.41
- 52 Week High
- HAFN $8.99
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- IDYA 33.96
- Support Level
- HAFN N/A
- IDYA $27.52
- Resistance Level
- HAFN N/A
- IDYA $32.67
- Average True Range (ATR)
- HAFN 0.00
- IDYA 1.44
- MACD
- HAFN 0.00
- IDYA -0.04
- Stochastic Oscillator
- HAFN 0.00
- IDYA 3.75
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.